Oncternal Therapeutics Inc Total Liabilities
Oncternal Therapeutics Inc total liabilities. Based on the latest financial reports, Oncternal Therapeutics Inc (ONCT) has total liabilities worth $6.45 Million USD as of September 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Oncternal Therapeutics Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Oncternal Therapeutics Inc (1999–2023)
Total liabilities of Oncternal Therapeutics Inc from 1999 to 2023. This chart illustrates how Oncternal Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Oncternal Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Oncternal Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Avrupa Minerals Ltd
V:AVU
|
Canada | CA$454.00K |
|
Shirpur Gold Refinery Limited
NSE:SHIRPUR-G
|
India | Rs7.39 Billion |
|
Lypsa Gems & Jewellery Limited
NSE:LYPSAGEMS
|
India | Rs503.60 Million |
|
Bakrieland Development Tbk
JK:ELTY
|
Indonesia | Rp2.79 Trillion |
|
Aruma Resources Ltd
AU:AAJ
|
Australia | AU$321.75K |
|
Elevai Labs, Inc. Common Stock
NASDAQ:ELAB
|
USA | $19.83 Million |
|
Golden Cross Resources Ltd
AU:GCR
|
Australia | AU$10.33 Million |
|
Innovation Beverage Group Limited
NASDAQ:IBG
|
USA | $1.86 Million |
Liability Composition Analysis (1999–2023)
This chart breaks down Oncternal Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Oncternal Therapeutics Inc asset portfolio.
Liquidity & Leverage Metrics
Oncternal Therapeutics Inc Total Liabilities Ratios Explained
Oncternal Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.71 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oncternal Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oncternal Therapeutics Inc (1999–2023)
The table below shows the annual total liabilities of Oncternal Therapeutics Inc from 1999 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $6.68 Million | -13.08% |
| 2022-12-31 | $7.68 Million | +40.57% |
| 2021-12-31 | $5.46 Million | -6.71% |
| 2020-12-31 | $5.86 Million | -21.18% |
| 2019-12-31 | $7.43 Million | +42.65% |
| 2018-12-31 | $5.21 Million | -34.67% |
| 2017-12-31 | $7.97 Million | +72.96% |
| 2016-12-31 | $4.61 Million | -84.72% |
| 2015-12-31 | $30.17 Million | -8.07% |
| 2014-12-31 | $32.82 Million | +566.98% |
| 2013-12-31 | $4.92 Million | -51.15% |
| 2012-12-31 | $10.07 Million | +59.64% |
| 2011-12-31 | $6.31 Million | -49.61% |
| 2010-12-31 | $12.52 Million | -81.16% |
| 2009-12-31 | $66.47 Million | -12.64% |
| 2008-12-31 | $76.09 Million | -5.84% |
| 2007-12-31 | $80.81 Million | +150.93% |
| 2006-12-31 | $32.21 Million | +248.85% |
| 2005-12-31 | $9.23 Million | +0.64% |
| 2004-12-31 | $9.17 Million | -94.52% |
| 2003-12-31 | $167.54 Million | +156.42% |
| 2002-12-31 | $65.34 Million | +47.85% |
| 2001-12-31 | $44.19 Million | +55.79% |
| 2000-12-31 | $28.37 Million | +1611.89% |
| 1999-12-31 | $1.66 Million | -- |
About Oncternal Therapeutics Inc
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS… Read more